A5010530746- Child and Adolescent Psychosocial and Emotional Development
- Attention Deficit Hyperactivity Disorder
- Treatment of Major Depression
- Suicide and Self-Harm Studies
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Bipolar Disorder and Treatment
- Mental Health Treatment and Access
- Mental Health Research Topics
- Tryptophan and brain disorders
- Maternal Mental Health During Pregnancy and Postpartum
- Functional Brain Connectivity Studies
- Stress Responses and Cortisol
- Resilience and Mental Health
- Digital Mental Health Interventions
- Electroconvulsive Therapy Studies
- Schizophrenia research and treatment
- Youth Substance Use and School Attendance
- Sleep and related disorders
- Psychosomatic Disorders and Their Treatments
- Child Abuse and Trauma
- Traumatic Brain Injury Research
- Substance Abuse Treatment and Outcomes
- Diet and metabolism studies
- Advanced MRI Techniques and Applications
- Early Childhood Education and Development
The University of Texas Southwestern Medical Center
2016-2025
Southwestern Medical Center
2013-2024
University of Cincinnati
2022
Cincinnati Children's Hospital Medical Center
2022
Mayo Clinic
2022
University of Miami
2021
University of California, Irvine
2021
National Institutes of Health
2021
The University of Texas MD Anderson Cancer Center
2021
Southwestern University
2013-2021
Objective: The aim of this study was to present the reliability and validity Children's Depression Rating Scale–Revised (CDRS-R) in adolescent age group. Method: Adolescents with symptoms depression were assessed using CDRS-R global severity functioning scales at screening, baseline, after 12 weeks fluoxetine treatment. Global improvement also week (or exit). Reliability analyzed Classical Test Theory (item-total correlations internal consistency) between other outcomes. Results: (n = 145)...
The authors sought to identify predictors of self-harm adverse events in treatment-resistant, depressed adolescents during the first 12 weeks treatment.Depressed (N=334) who had not responded a previous trial with an SSRI antidepressant were randomized switch either another or venlafaxine, without cognitive behavior therapy. Self-harm events, i.e., suicidal and non-suicidal self-injury assessed by spontaneous report for 181 participants, systematic weekly assessment last 153...
Major depressive disorder in adolescents is common and impairing. Efficacious treatments have been developed, but little known about longer-term outcomes, including recurrence.To determine whether who responded to short-term or received the most efficacious treatment would lower recurrence rates, identify predictors of recovery recurrence.Naturalistic follow-up study.Twelve academic sites United States.One hundred ninety-six (86 males 110 females) randomized 1 4 interventions (fluoxetine...
Objective The purpose of this study was to report on the outcome participants in Treatment Resistant Depression Adolescents (TORDIA) trial after 24 weeks treatment, including remission and relapse rates predictors treatment outcome. Method (ages 12–18 years) with selective serotonin reuptake inhibitor (SSRI)-resistant depression were randomly assigned either a medication switch alone (alternate SSRI or venlafaxine) plus cognitive-behavioral therapy (CBT). At week 12, responders could...
The authors compared fluoxetine and placebo in continuation treatment to prevent relapse of major depressive disorder children adolescents.After a detailed evaluation, adolescents 7-18 years age with were treated openly fluoxetine. Those who had an adequate response after 12 weeks, as indicated by Clinical Global Impression improvement score 1 or 2 decrease at least 50% Children's Depression Rating Scale-Revised score, randomly assigned receive for additional 6 months. primary outcome...
Article AbstractObjective: The Treatment for Adolescents with Depression Study (TADS) database was analyzed to determine whether suicidal events (attempts and ideation) occurred early in treatment, could be predicted by severity of depression or other clinical characteristics, were preceded deterioration symptoms increased irritability, akathisia, sleep disruption, mania.Method: TADS a 36-week randomized, controlled trial pharmacologic psychotherapeutic treatments involving 439 youths major...
The authors evaluated a sequential treatment strategy of fluoxetine and relapse-prevention cognitive-behavioral therapy (CBT) to determine effects on remission relapse in youths with major depressive disorder.Youths 8-17 years age depression were treated openly for 6 weeks. Those an adequate response (defined as reduction 50% or more the Children's Depression Rating Scale-Revised [CDRS-R]) randomly assigned receive continued medication management alone plus CBT additional months. was...
Major depression in adolescents is a significant public health concern because of its frequency and severity. To examine the neurobiological basis this population, authors studied functional activation characteristics brain before after antidepressant treatment antidepressant-naive depressed healthy comparison subjects.Depressed (N=19) (N=21) adolescents, ages 11 to 18 years, underwent MRI assessment while viewing fearful neutral facial expressions at baseline again 8 weeks later. The...
American youth are seriously impacted by depression and suicide. The Texas Youth Depression Suicide Research Network (TX-YDSRN) Participant Registry Study was initiated in 2020 to develop predictive models for treatment outcomes with and/or suicidality. This report presents the study rationale, design baseline characteristics of first 1000 participants. TX-YDSRN consists Hub (coordinating center), 12 medical school "Nodes" (manage/implement study), each 1–5 primary care, inpatient,...
The objective was to present naturalistic 1-year follow-up information of 96 child and adolescent outpatients with major depressive disorder who had been randomized in an 8-week double-blind, placebo-controlled trial fluoxetine. Subjects were children adolescents, ages 8-18 years, entered a clinical Following the acute treatment trial, not controlled. At 6 months 1 year, subjects parents interviewed using Kiddie Longitudinal Interval Follow-up Evaluation (K-LIFE) for course depression....
The authors sought to assess the relationship between candidate genes and two clinical outcomes, namely, symptomatic improvement occurrence of suicidal events, in a sample treatment-resistant depressed adolescents.
Objective: The Treatment for Adolescents With Depression Study (TADS) evaluates the effectiveness of fluoxetine, cognitive-behavioral therapy (CBT), and their combination in adolescents with major depressive disorder. authors report outcomes across a 1-year naturalistic follow-up period. Method: randomized, controlled trial was conducted 13 academic community sites United States. Stages I, II, III consisted 12, 6, 18 weeks acute, consolidation, continuation treatment, respectively. Following...
We examined the long-term outcome of participants in Treatment SSRI-Resistant Depression Adolescents (TORDIA) study, a randomized trial 334 adolescents (aged 12-18 years) with DSM-IV-defined major depressive disorder initially resistant to selective serotonin reuptake inhibitor (SSRI) treatment who were subsequently treated for 12 weeks another SSRI, venlafaxine, SSRI + cognitive-behavioral therapy (CBT), or venlafaxine CBT. Responders then continued same through week 24, while nonresponders...
The clinician-rated (QIDS-C₁₆) and self-report (QIDS-SR₁₆) versions of the 16-item Quick Inventory Depressive Symptomatology have been extensively examined in adult populations. This study evaluated both QIDS 17-item Children's Rating Scale - Revised (CDRS-R) an adolescent outpatient sample.Both QIDS-C₁₆ QIDS-SR₁₆ were completed for adolescents. Three different methods used to complete QIDS-C₁₆: (a) adolescents' responses clinician interviews; (b) parents' interview; (c) a composite score...